Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing

Archives of Dermatology

Volumn 134, Issue 8, 1998, Pages 963-967

  Saed, Ghassan M ^a   Ladin, Daniel ^a   Olson, Jennifer ^a   Han, Xuefei ^a   Hou, Zizheng ^a   Fivenson, David ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KELOID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCAR FORMATION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; WOUND HEALING;

EID: 0031880637     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.8.963     Document Type: Article

References (32)

1. Alhady S. Keloids in various races. Plast Reconstr Surg. 1969;44:564-566.
2. Ladin DA, Garner WL, Smith DJ. Excessive scarring as a consequence of healing. Wound Rep Reg. 1995;3:6-14.
3. Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS. Reduced growth-factor requirement of keloid derived fibroblasts may account for tumor growth. Proc Natl Acad Sci U S A. 1988;85:587-591.
4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
5. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1992;71:543-546.
6. Lane DP. p53: guardian of the genome. Nature. 1992;358:15-16.
7. Unger T, Nau MN, Segal S, Minna JD. p53: a transdominant regulator of transection whose function is ablated by mutations occurring in human cancer. EMBO J. 1992;11:1383-1390.
8. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849-852.
9. Hall PA, Mckee PH, Du P, Manage H, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 1993;8:203-207.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
11. Donehower L, Harvey M, Slagle B, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 1992;356:215-221.
12. Law J, Strong L, Chidambaram A, Ferrell R. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res. 1991;51:6385-6387.
13. Malkin D, Li F, Strong L, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1991;250:1233-1299.
14. Metzger AK, Sheffield VC, Duyk G, Daneshvark K, Edwards MS, Cogen PH. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci U S A. 1991;88:7825-7829.
15. Dantibanez KM, Birch JM, Hartley AL, et al. p53 germline mutations in Li-Fraumeni syndrome. Lancet. 1991;338:1490-1491.
16. Srivastava S, Zou Z, Pirollo K, Blanttner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumem syndrome. Nature. 1990;348:747-749.
17. Scheffner M, Werness BA, Hulbregtse JM, Levive AJ, Howley PM. The: E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
18. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 1992;357:82-85.
19. Debbas M, White E. Wild type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 1993;71:546-554.
20. Moran E. Interaction of adenoviral proteins with pRB and p53. FASEB J. 1993; 7:880-885.
21. Momand J, Xambetti GP, Olson DC, George DL, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell. 1992;69:1237-1245.
22. Oliner JD, Kinzler KW, Meitzer PS, Georges DL, Vogelstein B. Amplification of a gene encoding p53-associated protein in human sarcomas. Nature. 1992;358: 80-83.
23. Hou Z, Saed G, Fivenson D, Ladin D. Hypoxia does not alter cytokine production by keloid fibroblasts. J Invest Dermatol. 1995;104:669.
24. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci U S A. 1977;12:5463-5467.
25. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1319-1327.
26. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989;5:874-879.
27. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A. 1989;86:2766-2770.
28. Harris N, Brill E, Shihat O, et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 1986;6:4650-4655.
29. Romano JW, Ehrhart JC, Duthu A, Kim CM, Appella E, May P. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene. 1989;12:1483-1488.
30. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993;262:1980-1981.
31. Ladin D, Hou Z, Patel D, et al. p53, bcl-2, bcl-x and fas expression in keloids and keloid fibroblasts. J Invest Dermatol. 1996;108:580.
32. Saed G, Ladin D, Olson J, Han X, Fivenson D. p53 and apoptosis in the pathogenesis of keloids [abstract]. J Invest Dermatol. 1997;108:A580.